# MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients

> **NCT06237192** · NA · RECRUITING · sponsor: **National Research Center for Hematology, Russia** · enrollment: 200 (estimated)

## Conditions studied

- Precursor Cell Lymphoblastic Leukemia-Lymphoma

## Interventions

- **DRUG:** blinatumomab for B-ALL, venetoclax for T-ALL

## Key facts

- **NCT ID:** NCT06237192
- **Lead sponsor:** National Research Center for Hematology, Russia
- **Sponsor class:** NETWORK
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-01
- **Primary completion:** 2026-09-01
- **Final completion:** 2027-09-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06237192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06237192, "MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT06237192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*